These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11045437)

  • 1. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries.
    Heaney DC; Shorvon SD; Sander JW; Boon P; Komarek V; Marusic P; Dravet C; Perucca E; Majkowski J; Lima JL; Arroyo S; Tomson T; Ried S; van Donselaar C; Eskazan E; Peeters P; Carita P; Tjong-a-Hung I; Myon E; Taieb C
    Epilepsia; 2000; 41 Suppl 5():S37-44. PubMed ID: 11045437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy.
    Heaney DC; Shorvon SD; Sander JW
    Epilepsia; 1998; 39 Suppl 3():S19-25. PubMed ID: 9593232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of cost minimization of monotherapy antiepileptic treatment in patients with recent diagnosed epilepsy : the situation in Spain].
    Arroyo S; Fossas P; Nieto-Barrera M; Salas-Puig X; Sánchez-Alvarez JC; Serratosa JM; Soler-Singla L; Heaney DC; Sander JW; Shorvon S
    Rev Neurol; 2000 Nov 1-15; 31(9):828-32. PubMed ID: 11127083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.
    Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL
    Value Health; 2007; 10(3):173-82. PubMed ID: 17532810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK.
    Shakespeare A; Simeon G
    Seizure; 1998 Apr; 7(2):119-25. PubMed ID: 9627202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
    Zeng K; Wang X; Xi Z; Yan Y
    Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis.
    Chisholm D;
    Epilepsia; 2005 May; 46(5):751-9. PubMed ID: 15857443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy.
    Chen B; Choi H; Hirsch LJ; Katz A; Legge A; Buchsbaum R; Detyniecki K
    Epilepsy Behav; 2017 Nov; 76():24-31. PubMed ID: 28931473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of anti-epileptic drugs-an internet study.
    Wieshmann UC; Baker G
    Acta Neurol Scand; 2017 May; 135(5):533-539. PubMed ID: 27757951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiepileptic drugs in development: prospects for the near future.
    Leppik IE
    Epilepsia; 1994; 35 Suppl 4():S29-40. PubMed ID: 8174517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of antiepileptic pharmacotherapy in a tertiary referral center in South India: a pharmacoepidemiologic and pharmacoeconomic study.
    Radhakrishnan K; Nayak SD; Kumar SP; Sarma PS
    Epilepsia; 1999 Feb; 40(2):179-85. PubMed ID: 9952264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological outcomes in newly diagnosed epilepsy.
    Mohanraj R; Brodie MJ
    Epilepsy Behav; 2005 May; 6(3):382-7. PubMed ID: 15820347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the cost of epilepsy in Europe: a review with economic modeling.
    Pugliatti M; Beghi E; Forsgren L; Ekman M; Sobocki P
    Epilepsia; 2007 Dec; 48(12):2224-33. PubMed ID: 18088267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin.
    Steiner TJ; Dellaportas CI; Findley LJ; Gross M; Gibberd FB; Perkin GD; Park DM; Abbott R
    Epilepsia; 1999 May; 40(5):601-7. PubMed ID: 10386529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and costs of care for epilepsy: findings from a U.K. regional study.
    Jacoby A; Buck D; Baker G; McNamee P; Graham-Jones S; Chadwick D
    Epilepsia; 1998 Jul; 39(7):776-86. PubMed ID: 9670907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China.
    Hong Z; Qu B; Wu XT; Yang TH; Zhang Q; Zhou D
    Epilepsia; 2009 Oct; 50(10):2192-8. PubMed ID: 19583782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacoeconomics of the new antiepileptic drugs.
    Heaney D
    Epilepsia; 1999; 40 Suppl 8():25-31. PubMed ID: 10563592
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
    Markowitz MA; Mauskopf JA; Halpern MT
    Neurology; 1998 Oct; 51(4):1026-33. PubMed ID: 9781524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and adverse effects of established and new antiepileptic drugs.
    Mattson RH
    Epilepsia; 1995; 36 Suppl 2():S13-26. PubMed ID: 8784211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure.
    Gillham R; Kane K; Bryant-Comstock L; Brodie MJ
    Seizure; 2000 Sep; 9(6):375-9. PubMed ID: 10985991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.